CDH1 and cancer: Recently, studies have shown that upregulation of pAMPK can inhibit cancer cell migration and epithelial-mesenchymal transition (EMT) by regulating the classical transforming growth factor β (TGF-β) signaling pathway, resulting in the increased expression of E-cadherin and decreased expression of vimentin [20].